BPTS - Biophytis ticks higher after presenting COVID drug data at conference
2023-05-25 06:18:30 ET
- Biophytis ( NASDAQ: BPTS ) stock rose ~5% premarket on Thursday after the company said that it presented positive results from a phase 2-3 trial of Sarconeos (BIO101) in severe COVID-19 at the American Thoracic Society International Conference (ATS 2023).
- The study was called COVA.
- "It was an honour to present these positive data to the scientific and medical community, showing a 44% reduction with Sarconeos (BIO101) vs placebo in the risk of respiratory failure or early death in hospitalized patients with severe COVID-19," said Biophytis CEO Stanislas Veillet.
- Veillet added that the company was moving forward with preparing filings to apply for conditional marketing authorization (cMA) in Europe and emergency use authorization (EUA) in the U.S.
- Earlier this month, Biophytis said it filed a request with the European Medicine Agency (EMA) for a meeting to discuss pre-submission for the cMA of Sarconeos to treat severe COVID-19.
- BPTS +5.11% to $2.67 premarket May 25
For further details see:
Biophytis ticks higher after presenting COVID drug data at conference